MAWAG
AKRO

Mid-American Wealth Advisory Group’s Akero Therapeutics AKRO Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18
Closed -$960 – 65
2025
Q2 		$960 Buy
+18
New +$818 ﹤0.01% 293

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mid-American Wealth Advisory Group's AKRO Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 18 shares — an estimated $960 sold.

Mid-American Wealth Advisory Group first reported a position in AKRO in Q2 2025 and held it in 1 quarter. The position peaked at $960 in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 18 Akero Therapeutics shares in Q3 2025, an estimated $960.
  • Mid-American Wealth Advisory Group first reported a position in Akero Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Akero Therapeutics position peaked at $960 in Q2 2025.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.